Probiotix Health PLC - Unaudited Interim Results to 30 June 2025
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
Unaudited Interim Results to
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to
Key Financial Highlights
· Gross revenue +33% to
· Gross profit +33% to
· EBITDA loss (excluding share-based payments) reduced by 52% to
· Growth in all markets with sales outside
· Strong cash balance of
· Current trading robust with order book at a record level
Operational Highlights
· A number of new commercial partnerships secured across
· Appointment of new sales executive in the US expected to drive further growth in
· First commercial manufacturing of LPLDL completed through our CMO partnership in
· Launch of two new menopause-focused women's health concepts - YourBiotix MH and YourBiotix PMH
· Initiated discussions with the Steno Research Foundation in
"The successful product launches by our partners achieved over the past few years, and the accelerating consumer acceptance, confirms our belief in the tremendous long-term potential for the Company. We remain committed to executing the growth strategy to deliver sustainable value for shareholders, and look forward to reporting further on our progress."
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
|
|
|
|
|
|
|
|
Peterhouse Capital Limited Aquis Corporate Adviser and Broker |
|
|
|
Tel: 020 7469 0930 |
|
|
|
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the
Notes to Editors:
ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
Chief Executive Officer's overview
The first half of 2025 delivered strong and satisfactory progress across all areas of the business, with revenue growth exceeding previous years while maintaining gross margin profitability. The strategic execution and optimisation measures implemented in previous periods are beginning to show tangible results, providing a strong foundation for a sustainable full-year performance.
The Company continued to strengthen its position in core markets across
The sustained investment in R&D has resulted in the launch of new innovative products targeting the cross-over consumer segment between women's health and cardiometabolic health. These product introductions are gaining early traction, and reinforce our reputation as an innovative first mover and reliable provider of turnkey product solutions in the preventive cardiometabolic space.
The Company's focused strategy of working closely with contract manufacturers has started to deliver cost efficiencies, providing further opportunities to enhance long-term profitability .
Revenue for the first six months of 2025 reached
Strategic Outlook
Building on the solid track record of recent years, the Company remains committed to its vision of reaching
The Company's strategic pillars and KPIs remain focused around five core pillars:
· Commercial Expansion: accelerating organic growth by leveraging the existing product portfolio, targeting new regional and global customers within the dietary supplement sector. The efforts include expanding commercial platforms across
· Value Proposition: aim to broaden the market reach through a phased expansion from cholesterol-related products to encompass broader cardiometabolic health solutions, ultimately targeting the metabolic aspect of the healthy ageing segment.
· Customer Value & Barriers: reinforcement of the competitive position and increasing customer loyalty by offering finished-format, turnkey solutions to key market segments, thereby building barriers to entry for competitors.
· Product & Clinical Innovation: identification of new targeted, clinically documented strains and innovation of novel dosage formats, catering to specific consumer needs in the Healthy Ageing space. Expanding the science network and exploring new indication areas through clinical trials to support long-term growth.
· Cost Optimisation: the consolidation of manufacturing partnerships in
Progress Highlights
Commercial Development
During the first half of 2025, new commercial partnerships were successfully established and advanced across
· Two new product launches were successfully executed in H1 2025 with leading brands Solaray and Life Extension.
· The existing partnership with Seed delivered substantial growth, supported by Seed's ongoing success with existing products and aggressive expansion into new distribution channels.
· Significant efforts were made to position LPLDL as the leading cholesterol prevention supplement ingredient within direct-to-consumer and online distribution channels.
· Eifron (
· Key projects with European partners made notable progress, with potential launches anticipated in late 2025/early 2026.
· Existing European partnerships with HLH and Klinge Pharma continued to demonstrate positive growth trajectories as consumer awareness around cardiometabolic health increases.
· In
· Import and cross-border sales by Dancare into
· In
The Company maintains its instrumental focus on executing on the strategic pillars, and capitalising on market developments to drive sustainable growth and value creation for all stakeholders.
Marketing
· In the first half of the year, our marketing efforts have made significant strides in positioning the Company as a preferred partner among global B2B stakeholders.
· The Company successfully executed targeted direct marketing and outreach campaigns, to strengthen the sales project pipeline and expanded the engagement with key business partners.
· Comprehensive measurement frameworks to monitor and drive progress on active sales initiatives, ensuring a data-driven approach that supports sustainable growth was implemented.
These initiatives collectively enhance our market presence and lay a solid foundation for continued revenue expansion.
Operations
· The first commercial manufacturing of LPLDL was completed through the Company's strategic contract manufacturing partnership (CMO) in
· Significant progress in identifying additional European-based finished-format CMOs to diversify our manufacturing footprint was obtained. One new CMO is anticipated to join the existing network by the first half of 2026, further supporting risk mitigation and the optimisation of production costs.
Research & Development
· A comprehensive clinical protocol in collaboration with our commercial partner, Ornyx in
· Discussions with the Steno Research Foundation in
Organisational Development
To bolster our commercial activities in
Results
The Group delivered a strong trading performance during the period, with revenue increasing by 33% to
EBITDA loss, excluding share-based payment expense, improved markedly, reducing by 52% to
The net loss for the period reduced by 42% to
The Group concluded the period with cash and cash equivalents of
Outlook
We are pleased to report that the Company is firmly on track to deliver against our strategic objectives. Over the past few years, the Company has successfully established a solid organisational foundation with strengthened manufacturing capabilities, a burgeoning sales pipeline, and ongoing clinical development efforts. These crucial elements position the Company well to capitalise on and maintain a leading position within the rapidly growing market for cardiometabolic health and cholesterol-lowering supplements.
The increasing consumer awareness and market focus on preventive cardiometabolic supplement products continues to expand at an impressive pace (CAGR over the next 5-year period >8%), reflecting the growing demand for effective, science-backed health solutions. The successful product launches by our partners achieved over the last few years, and the accelerating consumer acceptance, confirms our belief in the tremendous long-term potential for the Company. The Board and Management remain committed to executing the growth strategy to deliver sustainable value for shareholders.
We extend our sincere gratitude to our shareholders for their continued support, patience, and dedication. Your confidence fuels our efforts, and together, we are confident in our ability to achieve our vision of becoming a leading provider in this dynamic and expanding market.
We look forward to updating you on our continued progress and future milestones.
Consolidated Statement of Comprehensive Income
For the 6 months to
|
|
|
|
6 months to 30 June 2025 Unaudited |
6 months to 30 June 2024 Unaudited |
Year ended 31 December 2024 Audited |
|
Continuing operations |
|
|
£'000 |
£'000 |
£'000 |
|
|
|
|
|
|
|
|
Revenue |
|
|
1,344 |
1,006 |
1,883 |
|
|
|
|
|
|
|
|
Cost of sales |
|
|
(596) |
(442) |
(886) |
|
|
|
|
─────── |
─────── |
─────── |
|
Gross Profit |
|
|
748 |
564 |
997 |
|
|
|
|
|
|
|
|
Share based payments |
|
|
(16) |
(10) |
(26) |
|
Depreciation and amortisation |
|
|
(25) |
(26) |
(68) |
|
Other administrative costs |
|
|
(860) |
(796) |
(1,755) |
|
|
|
|
|
|
|
|
|
|
|
─────── |
─────── |
─────── |
|
Total administrative expenses |
|
|
(901) |
(832) |
(1,849) |
|
|
|
|
─────── |
─────── |
─────── |
|
Operating (loss)/profit |
|
|
(153) |
(268) |
(852) |
|
|
|
|
|
|
|
|
Finance income / (costs) |
|
|
- |
- |
- |
|
|
|
|
─────── |
─────── |
─────── |
|
Profit/(Loss) before Income tax |
|
|
(153) |
(268) |
(852) |
|
|
|
|
|
|
|
|
Income tax |
|
|
3 |
7 |
5 |
|
|
|
|
─────── |
─────── |
─────── |
|
Profit/(Loss) for the period |
|
|
(150) |
(261) |
(847) |
|
|
|
|
|
|
|
|
Other Comprehensive Income |
|
|
- |
- |
- |
|
|
|
|
─────── |
─────── |
─────── |
|
Total comprehensive income for the period |
|
|
(150) |
(261) |
(847) |
|
|
|
|
═══════ |
═══════ |
═══════ |
|
|
|
|
|
|
|
|
Total comprehensive income attributable to the owners of the Group |
|
|
(150) |
(261)
|
(847)
|
|
|
|
|
═══════ |
═══════ |
═══════ |
|
|
|
|
(150) |
(261) |
(847) |
|
Earnings/(loss) per share |
|
|
|
|
|
|
Basic & Diluted - pence |
4 |
|
(0.09)p |
(0.21)p |
(0.63)p |
|
|
|
|
═══════ |
═══════ |
═══════ |
Consolidated Statement of Financial Position
As at
|
|
Notes |
As at 30 June 2025 Unaudited |
As at 30 June 2024 Unaudited |
As at 31 December 2024 Audited |
|
ASSETS |
|
£'000 |
£'000 |
£'000 |
|
Non-current assets |
|
|
|
|
|
Intangibles |
|
211 |
275 |
236 |
|
Property plant and equipment |
|
7 |
- |
7 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
218 |
275 |
243 |
|
|
|
─────── |
─────── |
─────── |
|
CURRENT ASSETS |
|
|
|
|
|
Inventories |
|
17 |
95 |
31 |
|
Trade and other receivables |
|
846 |
631 |
257 |
|
Cash and cash equivalents |
|
1,299 |
865 |
1,646 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
2,162 |
1,591 |
1,934 |
|
|
|
─────── |
─────── |
─────── |
|
TOTAL ASSETS |
|
2,380 |
1,866 |
2,177 |
|
|
|
═══════ |
═══════ |
═══════ |
|
EQUITY |
|
|
|
|
|
Shareholders' Equity |
|
|
|
|
|
Called up share capital |
5 |
79 |
61 |
79 |
|
Group reorganisation reserve |
|
(945) |
(945) |
(945) |
|
Share premium |
|
4,534 |
3,338 |
4,534 |
|
Share based payment reserve |
|
57 |
67 |
41 |
|
Retained Earnings |
|
(1,936) |
(1,241) |
(1,786) |
|
|
|
|
|
|
|
|
|
─────── |
─────── |
─────── |
|
Total Equity |
|
1,789 |
1,280 |
1,923 |
|
|
|
─────── |
─────── |
─────── |
|
LIABILITIES |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
538 |
520 |
194 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
538 |
520 |
194 |
|
|
|
─────── |
─────── |
─────── |
|
Non - current liabilities |
|
|
|
|
|
Deferred tax liability |
|
53 |
66 |
60 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
53 |
66 |
60 |
|
|
|
─────── |
─────── |
─────── |
|
TOTAL LIABILITIES |
|
591 |
586 |
254 |
|
|
|
─────── |
─────── |
─────── |
|
|
|
|
|
|
|
TOTAL EQUITY AND LIABILITIES |
|
2,380 |
1,866 |
2,177 |
|
|
|
|
|
|
|
|
|
═══════ |
═══════ |
═══════ |
Consolidated Statement of Changes in Equity
For six months to
|
|
Called up Share Capital |
Share premium |
Group Reorganisation reserve |
Share-based Payment reserve |
Retained Earnings |
Total Equity |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
61 |
3,338 |
(945) |
57 |
(980) |
1,531 |
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(261) |
(261) |
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
10 |
- |
10 |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
61 |
3,338 |
(945) |
67 |
(1,241) |
1,280 |
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(586) |
(586) |
|
|
|
|
|
|
|
|
|
Forfeiture of share options |
- |
- |
- |
(41) |
41 |
- |
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
15 |
- |
15 |
|
|
|
|
|
|
|
|
|
Share Issue |
18 |
1,208 |
- |
- |
- |
1,226 |
|
|
|
|
|
|
|
|
|
Share issue costs |
- |
(12) |
- |
- |
- |
(12) |
|
|
|
|
|
|
|
|
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
79 |
4,534 |
(945) |
41 |
(1,786) |
1,923 |
|
|
|
|
|
|
|
|
|
Loss for the period |
- |
- |
- |
- |
(150) |
(150) |
|
|
|
|
|
|
|
|
|
Share based payments |
- |
- |
- |
16 |
- |
16 |
|
|
|
|
|
|
|
|
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
|
Balance at |
79 |
4,534 |
(945) |
57 |
(1,936) |
(1,789) |
|
|
────── |
─────── |
─────── |
─────── |
────── |
─────── |
Consolidated Statement of Cash Flows
For the six months to
|
|
Notes |
6 months to 30 June 2025 Unaudited |
Period to 30 June 2024 Unaudited |
Year ended 31 December 2024 Audited |
|
|
|
£'000 |
£'000 |
£'000 |
|
Reconciliation of loss before income tax to cash outflow from operations |
|
|
|
|
|
Operating (loss)/profit |
|
(153) |
(268) |
(852) |
|
Decrease/ (Increase) in inventories |
|
14 |
8 |
72 |
|
(Increase)/decrease in trade and other receivables |
|
(589) |
(366) |
8 |
|
(Decrease)/increase in trade and other payables |
|
343 |
(46) |
(381) |
|
Share based payments |
|
16 |
10 |
26 |
|
Depreciation and amortisation |
|
25 |
26 |
53 |
|
Write off intangible asset |
|
- |
- |
14 |
|
Net Fx Difference |
|
(3) |
(1) |
- |
|
|
|
────── |
────── |
────── |
|
Net cash outflow from operations |
|
(347) |
(637) |
(1,060) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax received |
|
- |
- |
- |
|
|
|
────── |
────── |
────── |
|
Net cash (outflow)/inflow from operating activities |
|
(347) |
(637) |
(1,060) |
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
|
|
Purchase of intangible assets |
|
- |
- |
(10) |
|
|
|
────── |
────── |
────── |
|
Net cash (outflow)/inflow from investing activities |
|
- |
- |
(10) |
|
|
|
────── |
────── |
────── |
|
Cash flows from financing activities |
|
|
|
|
|
Share issue net of costs |
|
- |
- |
1,214 |
|
|
|
────── |
────── |
────── |
|
Net cash inflow from financing activities |
|
- |
- |
1,214 |
|
|
|
────── |
────── |
────── |
|
|
|
|
|
|
|
Increase/(decrease) in cash and equivalents |
|
(347) |
(637) |
144 |
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
|
1,646 |
1,502 |
1,502 |
|
|
|
────── |
────── |
────── |
|
Cash and cash equivalents at end of period |
|
1,299 |
865 |
1,646 |
|
|
|
══════ |
══════ |
══════ |
Notes to the results
For the six months to
1. General Information
ProBiotix Health plc is a company incorporated and domiciled in
The financial information set out in this report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the period ended
Copies of the annual statutory accounts and the Half Yearly report can be found on the Company's website https://probiotixhealth-ir.com/financials/latest-results
2. Basis of preparation and significant accounting policies
This report has been prepared using the historical cost convention, on a going concern basis and in accordance with
The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the accounting policies and making any estimates. Changes in assumptions may have a significant impact on the financial statements in the period the assumptions changed. The Board of Directors believe that the underlying assumptions are appropriate and that the financial statements are fairly presented. The Board of Directors believes that there are no areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, and therefore, these financial statements have limited disclosures.
3. Segmental Reporting
In the opinion of the directors, the Group has one class of business, in four geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. The Group sells into three highly interconnected markets, all costs assets and liabilities are derived from locations in the
Revenue analysed by geographical market
|
|
6 months 30 June 2025 |
6 months 30 June 2024 |
Year to 31 December 2024 |
|
|
£'000 |
£'000 |
£'000 |
|
|
34 |
14 |
34 |
|
US |
760 |
749 |
1,457 |
|
|
51 |
- |
- |
|
ROW |
499 |
243 |
392 |
|
|
────── |
────── |
────── |
|
|
1,344 |
1,006 |
1,883 |
|
|
══════ |
══════ |
══════ |
During the reporting period one customer represented
4. Earnings per Share
Basic earnings per share is calculated by dividing the earnings attributable shareholders by the weighted average number of ordinary shares outstanding during the period.
Reconciliations are set out below:
|
|
6 Months to Unaudited |
6 Months to Unaudited |
Year to Audited |
|
|
£ |
£ |
£ |
|
Basic & Diluted |
|
|
|
|
|
|
|
|
|
Earnings attributable to ordinary shareholders |
(150,056) |
(261,064) |
(847,631) |
|
|
|
|
|
|
Weighted average number of shares |
158,166,666 |
121,666,666 |
133,466,666 |
|
|
|
|
|
|
Earnings /(Loss) per-share - pence |
(0.09)p |
(0.21)p |
(0.63)p |
|
|
═════ |
═════ |
═════ |
|
|
|
|
|
As at
5. Share Capital
Issued share capital comprises:
|
Shares in issue |
|
|
|
|
|
Opening balance |
121,666,666 |
|
|
|
|
Share issue |
36,500,000 |
|
|
|
|
|
────── |
|
Closing balance at |
158,166,666 |
|
|
══════ |
|
Share capital |
£'000 |
|
|
|
|
Opening balance |
61 |
|
|
|
|
Share issue |
18 |
|
|
|
|
|
────── |
|
Closing balance at |
79 |
|
|
══════ |
6. Post balance sheet events
There are no post balance sheet events.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE